Top Botox Brands for Stellar Anti-Aging Results

Botox treatments have gained immense popularity over the years as an effective solution for reducing the appearance of wrinkles and fine lines. With a multitude of brands emerging in the market, it is essential to identify the most reputable ones that prioritize safety and efficacy. Several top brands have consistently been praised by both medical professionals and patients for providing exceptional results. To discover a comprehensive guide to the best botox treatment brands that ensure quality and reliable outcomes, continue reading below.

Illustration of botox treatment

Best brands of botox treatment in 2025

Allergan

Allergan, now part of AbbVie, is the leading producer of Botox, a botulinum toxin A treatment, which has been the gold standard in the market for over three decades. Approved for use in 98 countries, Allergan's Botox dominates the global market, with the company accounting for over half of the overall market value alongside other major players like Galderma and Merz Aesthetics. In 2022, the global botulinum toxin A market, led by Allergan, was valued at nearly $6.6 billion and is expected to grow at a CAGR of 6.5% to reach $10.2 billion by 2029. Botox is widely used for both cosmetic and therapeutic purposes, including treating glabellar frown lines, migraines, and excessive sweating, with its efficacy supported by over 528 peer-reviewed articles. The product's popularity is evident from the 3.6 million Americans who received botulinum toxin injections for aesthetic use in 2021.

Medytox

Medytox, a leading South Korean medical aesthetic company, has established itself as a prominent producer of botulinum toxin type A products, particularly with its flagship brand Neuronox. Since its launch in 2006, Neuronox has been registered in 32 countries and has sold over 12 million vials worldwide, making it the No.1 selling product in Korea and Thailand. Neuronox has demonstrated efficacy and safety comparable to Botox in various clinical studies, including a 1:1 dose ratio, and is used to treat a range of conditions from benign essential blepharospasm to moderate to severe glabellar wrinkles. For more detailed information, feel free to view the official product document of Neuronox.

Ipsen

Ipsen, through its brand Dysport, is a leading producer in the botulinum toxin market, renowned for its significant contributions to both aesthetic and therapeutic applications. Dysport, a type A botulinum toxin, has achieved robust sales growth, with a 30.5% year-over-year increase in the first quarter of 2023 and a 14.5% growth in FY 2023. Ipsen holds the second largest share in the global botulinum toxin market, accounting for 24% of the market share in 2021. The product's success is propelled by its widespread use in reducing facial wrinkles and fine lines, alongside its therapeutic uses. Ipsen's strong performance in the aesthetics market is expected to persist, contributing positively to the overall growth of the botulinum toxin market.

Revance Therapeutics

Revance Therapeutics is a leading biotechnology company renowned for its innovative botulinum toxin products, particularly DaxibotulinumtoxinA, which has been approved for treating glabellar lines and cervical dystonia. DaxibotulinumtoxinA, marketed as Daxxify, is a peptide-formulated neuromuscular blocking agent that has demonstrated a strong performance profile, with approvals in 2022 and 2023 for aesthetic and therapeutic indications. The drug has shown a high success rate in clinical trials, with Phase II drugs for Upper Limb Muscle Spasticity having an 89% phase transition success rate. Revance's product portfolio is set to expand under the acquisition by Crown Laboratories, valued at $924 million. This acquisition highlights the company's commitment to advancing neurotoxin research and its strong market presence. You can explore more about their innovative solutions on their official website.

Evolus

Evolus, the company behind the Jeuveau brand, has emerged as a significant player in the botox treatment market, particularly with its focus on millennial consumers and innovative marketing strategies. In 2021, Jeuveau saw a 76% increase in sales, reaching $99.7 million, and by 2023, it achieved an 11% market share in the U.S. neurotoxin category, with Botox holding 70%. The brand's success is attributed to its co-branded marketing programs and higher sales volumes, leading to a 33% year-over-year growth in the second quarter of 2023. Jeuveau is also expanding globally, with launches in Europe and plans for Australia, and it is positioned as a more affordable option, being 20-25% less expensive than Botox. With a strong performance and growing market presence, Evolus is poised to continue its upward trajectory. Learn more about their innovative approach on the Evolus website.

Hugel

Hugel, a leading global medical aesthetics company, has established itself as a top producer of botulinum toxin products, particularly with its brand Botulax (exported as Letybo). In the third quarter of 2024, Botulax sales surged by 41% year-over-year, reaching KRW 64.7 billion, with overseas sales jumping 73% driven by initial shipments to the US and robust growth in the Asia-Pacific market. The company achieved record-high earnings in 2022, with Botulax sales increasing by 28.9% and overall revenue rising by 21.5%. Hugel received FDA approval for Letybo in the US in March 2024, marking a significant milestone in its global expansion. With over 26 million vials sold in more than 50 countries, Botulax has solidified its position as a leading neurotoxin brand. For more detailed insights, explore Hugel's official website.

Sandoz

Sandoz, through its product Zytaze, is recognized for enhancing the efficacy of Botox treatments by combining zinc with phytase, which can extend the effects of Botox by up to 30%. This combination is crucial as zinc is necessary for Botox to realize its neurotoxic effects, and phytase accelerates zinc's breakdown in the body. To achieve this benefit, patients need to take two Zytaze pills a day for five days before their Botox injection. This supplement is particularly valuable because plain zinc supplements do not deliver the same results. The use of Zytaze can potentially reduce the frequency of Botox treatments, offering significant savings.

Daewoong Pharmaceutical

Daewoong Pharmaceutical's Nabota has established itself as a premier brand in the botulinum toxin market, boasting a 12% market share in the U.S. BTX market as of 2023, just five years after its FDA approval in 2019. Nabota, also known as Jeuveau in the U.S., has demonstrated non-inferiority to Botox with 87.2% of patients achieving a Glabellar Line Scale (GLS) score of 0 or 1 in global phase 3 trials. The product is manufactured using proprietary Hi-Pure Technology, ensuring over 98% purity. Nabota has secured approvals in 67 countries and is marketed in over 80 countries, with significant growth in regions like Southeast Asia and Central and South America. Its sales have seen a 93.3% year-over-year growth, contributing to Daewoong's record-breaking revenues. For more details on their revenue performance, visit Daewoong Pharmaceutical's revenue report.

Galderma

Galderma, through its brand Azzalure, is a leading producer in the botulinum toxin A market, capturing a significant share through its distribution agreement with Ipsen. Azzalure, sourced from Dysport, is specifically designed for aesthetic uses and has been widely used for various therapeutic and aesthetic applications. Galderma achieved record net sales of $2.2 billion in the first half of 2024, with a 10.8% year-on-year growth at constant currency, driven by volume growth and favorable mix, including a 13.4% growth in Injectable Aesthetics. The company's products, such as Azzalure and Dysport, are approved for treating moderate-to-severe glabellar lines and other wrinkles, showcasing their efficacy and safety in clinical studies. Galderma holds a substantial market share, with its flagship products contributing significantly to its annual sales.

Lanzhou Institute of Biological Products

Lanzhou Institute of Biological Products is a prominent producer of Botulinum Toxin Type A (CNBTX-A) in China, known for its high-quality and effective botox treatments. From 2015 to 2019, the sales value of Botulinum Toxin Type A in China grew significantly, with a Compound Annual Growth Rate (CAGR) of 13.9%, reflecting the product's increasing popularity and trust in the market. The institute's product, Hengli, competes alongside international brands like Botox by Allergan, highlighting its market competitiveness. The China botulinum toxin market, dominated by Type A products like those from Lanzhou Institute, is expected to reach a projected revenue of USD 1,443 million by 2030, growing at a CAGR of 11.8% from 2023 to 2030. This growth is driven by increasing demand for antiaging and aesthetic treatments, particularly among China's growing middle-class population.